Business
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital CHATHAM, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Tonix
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital\nCHATHAM, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an upcoming oral presentation by Ryo Otsuka, Ph.D., and poster presentation by Kohei Kinoshita, M.D at the 2023 American Transplant Congress (ATC). Both presenters are faculty members at the Center for Transplantation Sciences, Massachusetts General Hospital, and collaborators of Tonix. The Congress is being held June 3-7, 2023, in San Diego, Calif. The research involves studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L monoclonal antibody) for the prevention of renal and cardiac allograft rejection. A copy of the presentation and poster will be made available on the Scientific Presentations page of the Tonix website at www.tonixpharma.com following the congress. Oral Presentation DetailsTitle: Fc-Modified Anti-Cd154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic ComplicationsAuthors: R. Otsuka, G. Lassiter, T. Hirose, A. Karadagi, T. Tomosugi, I. Rosales, T. KawaiDate: Tuesday, June 6, 2023Time: 6:00 p.m. PTLocation: Ballroom 6E Upper Level, San Diego Convention Center, San Diego, Calif.Number: Presentation 544 Poster Presentation DetailsTitle: aCD154mAb (TNX-1500) Alone, or in Combination with Rapamycin, MMF, or aCD28mAb (VEL-101) Prolongs Cynomolgus Cardiac Allograft SurvivalAuthors: K. Kinoshita, A. Maenaka, Z. Habibabady, G. McGrath, R. Chaban, I. Ileka, M. Ma, V. Diaz, I. Rosales, S. Fogarty, P. Maguire, B. Daugherty, S. Lederman, R. Pierson IIIDate: Saturday, June 3, 2023Time: 5:30 – 7:30 p.m. PTLocation: Exhibit Halls A & B1, San Diego Convention Center, San Diego, Calif.Number: Poster Board A030 Tonix Pharmaceuticals Holding Corp.* Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyc...